HCM
CPRX

Hollencrest Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Hollencrest Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,510
Closed -$20.3K – 1083
2023
Q2 		$20.3K Buy
1,510
+1,025
+211% +$14.8K ﹤0.01% 657
2023
Q1 		$8.04K Sell
485
-603
-55% -$9.95K ﹤0.01% 777
2022
Q4 		$20.2K Buy
+1,088
New +$16.8K ﹤0.01% 612

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hollencrest Capital Management's CPRX Position: Q3 2023 in Review

Hollencrest Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2023, closing a stake of 1,510 shares — an estimated $20.3K sold.

Hollencrest Capital Management first reported a position in CPRX in Q4 2022 and held it in 3 quarters. The position peaked at $20.3K in Q2 2023. 255 funds tracked by Wall St. Rank hold CPRX as of Q3 2023.

  • Hollencrest Capital Management reported no remaining Catalyst Pharmaceutical position as of Q3 2023 after selling out during the quarter.
  • Hollencrest Capital Management sold 1,510 Catalyst Pharmaceutical shares in Q3 2023, an estimated $20.3K.
  • Hollencrest Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 3 quarters.
  • Hollencrest Capital Management's Catalyst Pharmaceutical position peaked at $20.3K in Q2 2023.
  • 255 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2023.

Based on Hollencrest Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.